VISTA. By: By: ----------------- ---------------------- Title: Title: ------------------- ------------------------ WITNESS: WITNESS: ------------ -----------------
VISTA. By: By: ----------------- ---------------------- Title: Title: ------------------- ------------------------ WITNESS: WITNESS: ------------ ----------------- Exhibit F July 27, 1995 To the Investors Listed on the Schedule of Investors to the Vista Medical Technologies, Inc. Series A-1 Preferred Stock Purchase Agreement dated July 27, 1995 Ladies and Gentlemen: We have acted as counsel for Vista Medical Technologies, Inc., a California corporation (the "Company"), in connection with the issuance and sale of shares of its Series A-1 Preferred Stock pursuant to the Vista Medical Technologies, Inc. Series A-1 Preferred Stock Purchase Agreement dated July 27, 1995 (the "Stock Purchase Agreement") between the Company and you. This opinion is being rendered to you pursuant to Section 4.7 of the Stock Purchase Agreement in connection with the Closing of the sale of the Series A-1 Preferred Stock. Capitalized terms not otherwise defined in this opinion have the meanings assigned to them in the Stock Purchase Agreement. In connection with the opinions expressed herein we have made such examination of matters of law and of fact as we considered appropriate or advisable for purposes hereof. As to matters of fact material to the opinions expressed herein, we have relied upon the representations and warranties as to factual matters contained in and made by the Company pursuant to the Stock Purchase Agreement and upon certificates and statements of government officials and of officers of the Company. We have also examined originals or copies of such corporate documents or records of the Company as we have considered appropriate for the opinions expressed herein. We have assumed for the purposes of this opinion that the signatures on documents and instruments examined by us are authentic, that each document is what it purports to be, and that all documents submitted to us as copies conform with the originals, which facts we have not independently verified. In rendering this opinion we have also assumed: (A) that the Stock Purchase Agreement and the Investors' Rights Agreement attached as Exhibit D thereto (the "Investors' Rights Agreement") have been duly and validly executed and delivered by you or on your behalf and constitute valid, binding and enforceable obligations upon you; (B) that the representations and warranties made in the Stock Purchase Agreement by you are true and correct; (C) that any wire transfers, drafts or checks tendered by you will be honored; (D) if...
VISTA. Subject to Clause 2.1 the Trustee shall hold the Trust Fund and the income thereof upon the trusts and with and subject to the powers and provisions of this Settlement.
VISTA. The term "Vista" shall mean Vista Healthcare Inc., a Texas business corporation.
VISTA. VA will provide the Contractor access to VISTA, VA's patient record computer system, Computerized Patient Record System (CPRS) that contains: patient medical records, medication profiles, laboratory and radiology data, and other diagnostic test results. Access will be for the purpose of:
VISTA a. May discontinue this agreement and any salary packaging at any time on two weeks’ notice without providing any reason.
b. Is not responsible for any loss or damage caused by way of discontinuance
c. Is not responsible for any loss or damage caused by way of delayed or misdirected payments.
VISTA com shall indemnify, hold harxxxxx xxx, at its sole expense, xxxxxx YP.Net and any of YP.Net's subsidiaries, affiliates, directors, officxxx, xmployees, agxxxx xnd independent contractors from and against any and all third-party claims, suits, proceedings, costs and expenses (including attorneys' fees), liabilities, losses and damages (collectively, "Third-Party Claims") arising out of, or in any way related to:
(i) Any actual or alleged breach of this Agreement or violation of applicable U.S. lawbyVista.com;
(ii) Any Vista.com Content or Xxxxx.xxx Xrand Features, xxgardless of wxxxx xxxated; or
(iii) The development, operation, maintenance and hosting of the YP.Net Private Label Service, excluding user registration for that Service and any YP.Net Materials or YP.Net Brand Features xxxxlayed in connection therewith,
VISTA com's obligations under Section 9.1.1 shall be contingent on XX.Xxx
(x) Providing Vista.com with reasonably prompt written xxxxxx of any such Third-Party Claim, for which it is seeking a defense and/or indemnification hereunder;
(ii) Fully cooperates with, and provides information or other assistance to, Vista.com upon request and at Vista.com's xxxxxxx; and
(iii) Allows Vista.cox xx xxxxrol the defense and resolution xx xny such Third-Party Claim with legal counsel of Vista.com's choice. Notwithstanding Section 9.1.2(iii) above, YP.Nex xxxxx xave the right to approve the settlement of any Thirx-Xxxxy Claim, which involves an admission or commitment by or on behalf of YP.Net, other than the payment of money to be fully indemnified herxxxxxx by Vista.com. Such approval shall not be unreasonably withheld or xxxxxxx.
VISTA. For Aim 3, we used data collected as part of VISTA. In VISTA, African American women with SLE ages 20 – 50 were recruited from the GOAL Cohort. African American women without SLE ages 20 – 50 were recruited from marketing lists to reflect the geographic distribution of women with SLE recruited from GOAL. All women self-identified as African American, were premenopausal and did not have a history of clinical CVD at the time of study enrollment. Women without SLE enrolled into the comparison group were also free of any other autoimmune or chronic inflammatory diseases. All participants attended a clinic visit and completed a questionnaire on demographics, reproductive and health history, behaviors and experiences of stress and support. Participants had their height, weight and blood pressures measured by trained study staff. At this visit, participants also had a carotid ultrasound assessment. Female participants in GLR/GOAL were linked to Georgia birth certificates from 1994 – 2018 on which they are identified as the mother. Data linkages were conducted by the Georgia Department of Public Health (GA DPH). The GA DPH used a multi-stage matching algorithm using combinations of various identifying keys. The identified sample of birth certificates consisted of births both before and after SLE diagnosis. A comparison set of birth certificates to the general population that reflected the racial, age and geographic distribution of the SLE sample was obtained from the National Center for Health Statistics. Participants in GLR/GOAL were also linked to Georgia inpatient hospital discharge records from 2000-2013. The linkage was conducted by the GA DPH using the same methods as the birth certificate linkage. Discharge records also contain a principal diagnosis and 9 secondary diagnoses indicating the reason(s) for the hospitalization. Diagnoses are coded using the International Classification of Diseases 9th Revision Clinical Modification (ICD-9-CM). Finally, participants in the GLR/GOAL were also linked to death records in the National Death Index (NDI). Death records contain date of death and causes of death identified by ICD- 10 codes.
